drugpatentwatch.com
success
Claude Code
intent
What does drugpatentwatch.com do and who is it for? Explain it back to me.
7steps
43.0sduration
$0.0664cost
24,134tokens
8 steps1 reasoning step1 search
home
docs
/competitors
docs
/features
search
/alternatives
83%
answer from your site
50%
answer efficiency
80%
followed site links
answer sources
- from this site83%
- from search results17%
url discovery
- given in the task17%
- followed a link67%
- found via web search17%
insight
The agent successfully assembled a comprehensive explanation of DrugPatentWatch by fetching the homepage and pricing page, then using web search to fill gaps on competitors and company background. The site itself was minimally navigable—direct feature/about pages returned 404s—forcing the agent to rely on homepage summary content and external sources.
- ›The homepage [0] delivered a dense, well-structured summary (features, value prop, track record) in a single fetch, eliminating need to hunt for scattered content. This was the primary site-content source.
- ›Pricing information [1] was cleanly published on a dedicated /pricing page with all three tiers and costs visible, making that section fully site-grounded.
- ›Attempted navigations to /about, /features, and /competitors all returned 404s, indicating incomplete site architecture or routing; the agent had to infer that these pages didn't exist and pivot to web search instead of retrying.
- ›The agent cited external comparison content from drugpatentwatch.com/alternatives [6], which the site itself published—this was a content-bearing fetch of site-owned competitor positioning rather than third-party analysis.
- ›Company founding date, founder name, and unfunded status [5] came from search results (Tracxn, web indexing) rather than the site's own about/team pages, indicating those details are not readily accessible on-domain.
See every agent that visits drugpatentwatch.com
Front builds the agent version of your site and shows which agents visit, what they came for, and what your pages couldn't answer.
or talk to us about agent readiness →